Clinical trials: copd or chronic obstructive
COPD
Assessing Exercise Capacity After PulseHaler™ Treatment in GOLD II-IV COPD Patients
Prospective, sham controlled, interventional study to evaluate the extent to which PulseHaler improves the functional status of Chronic Obstructive Lung Disease (GOLD) II-IV Chronic obstructive pulmonary disease (COPD) patients.
- Trial name
- NCT04236076
- Testing
- PulseHaler
- Volunteers
- 104 people
- Sponsor
- Respinova LTD
COPD, Copd Bronchitis
Muco-ciliary Cleansing of Lungs in COPD With and Without a Salt Particle Inhaler
Cross-over trial of the effect of a salt particle inhaler on pulmonary muco-ciliary cleansing in COPD patients as measured by lung scintigraphy.
- Trial name
- NCT03927365
- Testing
- Inhalation from a salt particle inhaler with or without content
- Where
- Denmark
- Volunteers
- 35 people
- Sponsor
- Liita Care ApS
Emphysema, COPD
Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)
This is a prospective, open-label, multi-center, single-arm study to be conducted at up to 20 investigational sites. The Study plans to enroll up to 140 subjects with severe emphysema and collateral ventilation in the target…
- Conditions
- Emphysema, COPD, Severe Emphysema
- Trial name
- CONVERT (NCT04559464)
- Testing
- AeriSeal, Zephyr Valves
- Where
- 14 sites in Australia, France and 5 more
- Volunteers
- 102 people
- Sponsor
- Pulmonx Corporation
Opioid-Induced Constipation
Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the long-term safety and tolerability of CB-5945 for the treatment of opioid-induced constipation (OIC) in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01696643
- Testing
- CB-5945
- Volunteers
- 1,407 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Chronic Sinusitis With Nasal Polyps and Eosinophilia
Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia
Phase 2, open-label, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 6 months in subjects with chronic sinusitis with nasal polyps and eosinophilia.
- Trial name
- CS201 (NCT02217332)
- Testing
- dexpramipexole
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Knopp Biosciences
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
Examine the effects of TI in combination with an anti-diabetic regimen including inhaled insulin versus anti-diabetic treatment without inhaled insulin on lung function \& pulmonary safety
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT00642616
- Testing
- Technosphere® Insulin, Usual Care
- Where
- 21 sites in United States, Russia and 1 more
- Volunteers
- 34 people
- Sponsor
- Mannkind Corporation
COPD (Chronic Obstructive Pulmonary Disease)
Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients
This multicenter, retrospective-prospective, cohort study aims to evaluate the effectiveness and safety of Extra-fine Beclometasone Diproprionate/Formoterol Fumarate/Glycopyrronium Bromide (EF-BDP/FF/GB) therapy in adults with…
- Trial name
- RETRIBUTE (NCT07406048)
- Testing
- BDP/FF/GB (100ug/6ug/12.5ug)
- Where
- Brazil
- Volunteers
- 396 people
- Sponsor
- Chiesi Farmaceutica Ltda.
Cystic Fibrosis, Chronic Obstructive Pulmonary Disease
A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects
This is a randomized, double-blind, cross-over, vehicle-controlled study to determine whether GS-5737 in 2.8% saline accelerates mucociliary clearance (MCC) in healthy subjects, compared to vehicle of 2.8% saline alone.
- Trial name
- NCT01793649
- Testing
- GS-5737
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1b Study of PUR1800 in Patients With COPD
This is a randomised, placebo-controlled, double-blind 3-way crossover study in which PUR1800, or placebo is dosed daily for 14 consecutive days in adult subjects with stable COPD over three discrete TPs.
- Trial name
- NCT04759807
- Testing
- PUR1800 250 ug, PUR1800 500 ug
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Pulmatrix Inc.
Study is Being Conducted in Healthy Volunteers
A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers
This study will be conducted to establish the relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with and without a spacer device.
- Trial name
- NCT02934607
- Testing
- Symbicort pMDI with spacer device, Symbicort pMDI without spacer device
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)
To investigate possible problems or questions in safety and effectiveness of salmeterol and fluticasone in patients with chronic obstructive pulmonary disease (bronchitis chronic / emphysema).
- Trial name
- NCT01332409
- Testing
- Salmeterol and Fluticasone
- Where
- Japan
- Volunteers
- 2,000 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease
The objective of this study was to compare the bronchodilator efficacy and safety of ipratropium bromide HFA-134a inhalation aerosol and marketed, Atrovent® CFC Inhalation Aerosol in COPD patients
- Trial name
- NCT02260011
- Testing
- Ipratropium bromide HFA-134a inhalation aerosol, Atrovent® CFC inhalation aerosol
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
COPD (Chronic Obstructive Pulmonary Disease)
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD.
- Trial name
- STRIDE (NCT07612878)
- Testing
- Cohort 1: Dupilumab, Cohort 2: usual care only
- Where
- 7 sites in United States
- Volunteers
- 350 people
- Sponsor
- Sanofi
Pulmonary Disease, Chronic Obstructive
Evaluating the Clinical Effectiveness of a Patient-specific Silicone Stent
The goal of the trial is to establish a method, material, and patient-specific stent design that will last longer, fit better, and cause less trauma to the airway and the patient.
- Trial name
- NCT05050591
- Testing
- Patient-Specific Silicone Airway Stent
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- VisionAir Solutions
Pulmonary Disease, Chronic Obstructive
Ba253BINEB Compared to Ba253MDI (Metered Dose Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to investigate the efficacy and safety of Ba253BINEB during the continuous 4 weeks administration to the patients with COPD using Ba253MDI (Tersigan® aerosol) as the comparator drug.
- Trial name
- NCT02182583
- Testing
- Ba253MDI, Ba253BINEB
- Volunteers
- 163 people
- Sponsor
- Boehringer Ingelheim
COPD, Arrhythmia
Perry Virtual - A Prospective and Observational Rural Health Trial
The principal objective of the study is to determine if patient-empowered, real-time and home- based patient monitoring of vital parameters can lead to: Reduction in admission rates and improved clinical management of chronically…
- Conditions
- COPD, Arrhythmia, Murmur, Heart, Chronic Disease
- Trial name
- NCT04483154
- Testing
- Coala Heart Monitor
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Coala Life, Inc
Pulmonary Disease, Chronic Obstructive
A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to assess the safety and efficacy of a single dosage strength of GW685698/GW642444 in subjects with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT00731822
- Testing
- GW685698/GW642444
- Where
- 9 sites in Norway, Sweden
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events
Background: Recent observational studies have reported possible arrhythmogenic effects with long-acting beta-agonists (LABA), while the long-acting anticholinergic tiotropium has been associated with cardiovascular and…
- Trial name
- NCT02096731
- Where
- Canada
- Volunteers
- 115,397 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)
Primary Objective To demonstrate that CHF 1535 pMDI is non-inferior to Symbicort® Turbohaler® in terms of pulmonary function (change from baseline in pre-dose morning FEV1 at Week 24) in patients with COPD.
- Trial name
- FORSYYN (NCT03888131)
- Where
- 53 sites in China
- Volunteers
- 750 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers
This study is an open label, randomized, three-way crossover study to assess the effect of particle size on the PK and safety of single inhaled doses of AZD7594 in healthy subjects (males aged 18 to 55 years [inclusive]).
- Trial name
- NCT02928354
- Testing
- Treatment A - AZD7594, Treatment B - AZD7594, Treatment C - AZD7594
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.